Lexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.10), FiscalAI reports.

Lexeo Therapeutics Price Performance

Shares of LXEO stock opened at $2.87 on Monday. The stock has a market cap of $235.48 million, a PE ratio of -2.50 and a beta of 1.64. The stock has a 50-day moving average of $3.38 and a 200-day moving average of $5.01. Lexeo Therapeutics has a one year low of $2.55 and a one year high of $10.99.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC acquired a new stake in Lexeo Therapeutics in the second quarter worth $6,932,175. Frazier Life Sciences Management L.P. raised its stake in Lexeo Therapeutics by 9.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,824,725 shares of the company’s stock worth $22,459,000 after buying an additional 400,000 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new stake in Lexeo Therapeutics during the 2nd quarter worth $1,237,000. Nantahala Capital Management LLC bought a new position in Lexeo Therapeutics during the second quarter worth about $6,051,500. Finally, Bank of America Corp DE bought a new position in Lexeo Therapeutics during the second quarter worth about $2,282,000. Institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

LXEO has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday. Wall Street Zen cut Lexeo Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Raymond James Financial reiterated a “strong-buy” rating on shares of Lexeo Therapeutics in a report on Tuesday, September 22nd. Leerink Partners reiterated an “outperform” rating and issued a $15.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday, September 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Lexeo Therapeutics in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $16.43.

Read Our Latest Report on LXEO

Lexeo Therapeutics Company Profile

(Get Free Report)

Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.

Read More

Earnings History for Lexeo Therapeutics (NASDAQ:LXEO)

Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.